Sort   by:  
 Page size 
ProteomicsInterindividual Variability in Imatinib Metabolism in Human Liver Microsomes and Primary Human Hepatocytes: Impact of CYP2C8 and CYP3A Phenotypes
Imatinib is a tyrosine kinase inhibitor (TKI) indicated for chronic myeloid leukemia (CML) and other cancers. It is metabolized by CYP2C8 and CYP3A into a major active metabolite N-desmethyl-imatinib. The purpose of the study was to determine in vitro the influence of CYP2C8 and CYP3A phenotypes, su...
ORGANISM(S): Homo sapiens (Human) 
2025-12-13 | PXD066482 | Pride
ProteomicsA Novel Approach for Generating Antigen Interference-Free Anti-Peptide Polyclonal Antibodies for Quantitative Measurements of Low-Abundance Protein Biomarkers Using Ultra-Sensitive Anti-Peptide Immunocapture LC-MS/MS Assays
Antigen interference from residual antigen peptides remains a persistent challenge in anti-peptide immunocapture liquid chromatography-tandem mass spectrometry (IC-LC-MS/MS) assays for quantifying low-abundance protein biomarkers. In this manuscript, we introduce a novel approach that utilizes carri...
ORGANISM(S): Homo sapiens (Human) 
2026-09-04 | PXD076272 | Pride
Stable isotopically labeled peptide antigen Anti-peptide immunocapture Protein biomarker Antigen interference Lc-ms/ms 
ProteomicsImpact of Variation in CYP3A and CYP2C8 on Tucatinib Metabolic Clearance in Human Liver Microsomes
Tucatinib is a tyrosine kinase inhibitor (TKI) indicated for HER2 positive breast cancer. It is metabolized primarily by cytochrome P450 (CYP) 2C8 and CYP3A. Given the interindividual variability in the pharmacokinetics of some TKIs, this study explored how variability in CYP2C8 and CYP3A activities...
ORGANISM(S): Homo sapiens (Human) 
2025-04-17 | PXD057282 | Pride
Quantitative proteomics M-class acquity Kinase inhibitor Triple quadrupole 7500 
UnknownDevelopment, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.
Not available
S-EPMC6538536 | biostudies-literature
ProteomicsDevelopment of an In Vitro Metabolic Dysfunction-Associated Steatohepatitis Model to Investigate Altered Drug Metabolizing Enzymes, Transport Proteins, and Hepatobiliary Disposition
Metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to affect approximately 30% of adults worldwide. The progressive form of MASLD, namely metabolic-dysfunction steatohepatitis (MASH), is a leading cause of chronic liver disease. MASH is marked by hepatocellular fat accumul...
ORGANISM(S): Homo sapiens (Human) 
2025-12-12 | PXD071083 | Pride
Human Lc-msms Schh Mash 
ProteomicsSILAC-based Quantitative Proteomic Analysis Unveiled the Arsenite-induced Perturbation of Multiple Pathways in Human Skin Fibroblast Cells
Humans are exposed to arsenic species through inhalation, ingestion and dermal contact, which may lead to skin, liver, and bladder cancers as well as cardiovascular and neurological diseases. The mechanisms underlying the cytotoxic and carcinogenic effects of arsenic species, however, remain incompl...
ORGANISM(S): Homo sapiens (Human) 
2018-10-26 | PXD005646 | Pride
Mass spectrometry Arsenite Silac Oxidative stress Quantitative proteomics 
MetabolomicsCharacterizing COPD phenotypes with a targeted signaling lipids metabolomics approach

A targeted metabolomics approach reveals distinct metabolic patterns associated with different GOLD stages, KNGF profiles and SYS subtypes in COPD patients, highlighting unique mechanisms and pathways underlying various COPD classification systems.

2025-07-21 | MTBLS11748 | MetaboLights
MetabolomicsSurvival of the littlest: Navigating sepsis diagnosis beyond inflammation in preterm neonates
Background Sepsis diagnosis in preterm neonates is challenging due to symptom overlap with non-infectious inflammatory conditions, and slow, unreliable diagnostic practices. This study aims to identify metabolic biomarkers to elucidate sepsis pathophysiology, and enable timely, accurate diagnosis, w...
2025-07-07 | MTBLS10665 | MetaboLights
ProteomicsN-Acetyltransferase (NAT) 1 and NAT2 Enzyme Activities Drive Interindividual Variability in Sulfamethoxazole N-Acetylation
Sulfamethoxazole (SMX) is associated with idiosyncratic drug induced liver injury (DILI), which remains difficult to predict. SMX is primarily metabolized by the N-acetyltransferases NAT1 and NAT2 to form N4-acetyl sulfamethoxazole (NA-SMX) and by cytochrome P450-mediated oxidation to form SMX-hydro...
ORGANISM(S): Homo sapiens (Human) 
2025-12-06 | PXD066786 | Pride
Sort   by:  
 Page size